UAE Influenza Vaccine Report 2026: Seasonality, Procurement, Payer Access, and Competitive Landscape

The UAE seasonal influenza vaccine market is estimated at USD 65–80 million in wholesale value for the 2026–2027 season, on volumes of roughly 3.0–3.6 million doses distributed across public and private channels. Growth has been running at 8–11% CAGR since 2022 as mandatory occupational vaccination in healthcare, education, and hospitality sectors continues to expand, and as private employer schemes bundle influenza cover into annual wellness benefits. Abu Dhabi (DOH) and Dubai (DHA) together account for roughly 85% of dosed volume, with MOHAP-regulated northern emirates making up the balance. Approximately 55–60% of doses move through public tenders (MOHAP, DOH, SEHA, Dubai Health) and the remainder through private hospitals, retail pharmacy chains (Aster, Life, BinSina, Boots) and corporate on-site clinics.

The UAE influenza season is bi-modal but skewed to the cooler months. Circulation typically starts building in October–November as expatriate travel from the northern hemisphere resumes, peaks between December and February when indoor gatherings intensify during the winter tourism season, and shows a smaller secondary wave in April–May tied to Umrah and regional pilgrimage traffic. As a result, the UAE public procurement cycle is calibrated for Northern Hemisphere (NH) formulation availability: MOHAP typically issues its national influenza guidance in August, DOH and DHA update their circulars in September, and mass vaccination campaigns in public primary healthcare centres run from mid-September through December. Manufacturers who miss the NH release window generally lose that season entirely, because Southern Hemisphere strains are not licensed for UAE reimbursement.

The UAE runs three parallel influenza procurement systems layered on top of federal MOHAP registration. MOHAP conducts a federal tender covering primary healthcare centres in Sharjah, Ajman, Ras Al Khaimah, Umm Al Quwain, and Fujairah, plus federal ministries and armed forces. DOH oversees Abu Dhabi, where SEHA (Abu Dhabi Health Services Company) is the dominant institutional buyer through its Ambulatory Healthcare Services network of family medicine centres, and Daman/Thiqa formularies drive private-channel reimbursement. DHA runs Dubai, where Dubai Health (formerly DHA hospitals) procures for public facilities and the Dubai Insurance framework governs private-plan formularies. Each authority publishes its own preferred product list, negotiates volume commitments separately, and defines which formulations (quadrivalent standard-dose, high-dose, cell-based, adjuvanted) qualify for reimbursement in the coming season.

The UAE public formularies currently reimburse quadrivalent inactivated influenza vaccine (QIV) as the standard of care across all age groups from 6 months, with expanded formulations layered in for defined risk populations. Sanofi (Vaxigrip Tetra, Fluzone High-Dose Quadrivalent, and Efluelda in older adults), GSK (Fluarix Tetra, and FluLaval Tetra in select channels), Seqirus/CSL (Flucelvax Tetra cell-based, Fluad Tetra MF59-adjuvanted), and Abbott/Mylan-Viatris (Influvac Tetra) are the principal originators active in the market. Cell-based QIV (Flucelvax) has been gaining share in premium private hospital and corporate channels since 2024, high-dose and adjuvanted formulations are increasingly reimbursed for adults 65+ in DOH-funded programs, and nasal live-attenuated vaccine (FluMist Quadrivalent) remains a niche private-only option for paediatric use. Local repackaging and last-mile cold chain is dominated by Julphar, NPI, and specialised Gulf distributors.

UAE public health guidance from MOHAP, DOH, and DHA identifies six priority populations for annual influenza vaccination: children aged 6 months to 5 years, adults aged 65 and above, pregnant women in any trimester, patients with chronic cardiovascular, respiratory, renal, or metabolic conditions, healthcare workers across all licensed facilities, and residents and staff of long-term care and disability support settings. Coverage in healthcare worker programs regularly exceeds 85% under mandatory workplace policies enforced by DHA, DOH, and MOHAP occupational licensing rules. Coverage in the elderly is estimated at 55–65% and rising, while paediatric coverage in the 6–59 month band remains meaningfully below WHO targets at an estimated 35–45%, representing the largest upside volume opportunity for manufacturers who can support demand generation with authorities.

Insurance is the single largest driver of private-channel influenza demand in the UAE. Under the Dubai Insurance Law and the Abu Dhabi mandatory health insurance framework, all residents must carry a health plan; the Essential Benefits Plan (Dubai) and Thiqa/enhanced Daman schemes (Abu Dhabi) explicitly include seasonal influenza vaccination for eligible members without co-payment when administered in-network. Large private insurers — Daman, Sukoon (formerly Oman Insurance), ADNIC, MetLife, AXA, Cigna, and Neuron/Nextcare as third-party administrators — negotiate direct-billing arrangements with pharmacy chains and hospital groups that determine which formulations members can access without out-of-pocket cost. Corporate wellness schemes at UAE-headquartered groups, financial institutions, and government-related entities routinely fund on-site influenza clinics from September to November, and BioNixus tracks brand preference and product mix at scheme level.

Community pharmacy has become the dominant point of administration for adult influenza vaccination in the UAE, particularly in Dubai and the northern emirates. Chains including Aster, Life, BinSina, Boots, Al Manara, Health First, and Planet have expanded pharmacist-administered vaccination services under DHA and MOHAP scope-of-practice extensions granted from 2022 onward, with walk-in and appointment-based clinics running throughout the September–December window. Hospital outpatient and family medicine clinics remain the primary channel for paediatric doses, pregnant women, and immunocompromised patients whose vaccination is medically supervised. Public primary healthcare centres — SEHA Ambulatory (Abu Dhabi), Dubai Health primary care, and MOHAP PHCs — anchor the free-of-charge campaigns for UAE nationals and priority residents. On-site corporate clinics, run by third-party providers such as Prime Health, Medcare, and Cleveland Clinic Healthy Aging, capture a growing share of the working-age dose volume.

The UAE aligns its seasonal influenza guidance with the WHO Northern Hemisphere strain recommendation issued in February–March each year. MOHAP's National Immunisation Technical Advisory Group (NITAG) formally reviews the WHO recommendation, epidemiological trends from national sentinel surveillance sites, and safety data from the previous season before endorsing target formulations and priority populations for the year. DOH and DHA subsequently issue emirate-level circulars that operationalise the federal guidance for their licensed facilities. National surveillance is coordinated through MOHAP-linked sentinel labs, SEHA laboratories in Abu Dhabi, and Dubai Health labs, feeding into WHO FluNet reporting. Manufacturers seeking public reimbursement need registration with MOHAP's Drug Department well ahead of season, plus formulary listing decisions from DOH, DHA, SEHA, and Dubai Health that typically finalise in Q2 for delivery in Q3–Q4.

BioNixus supports influenza vaccine manufacturers with UAE-specific primary research and secondary intelligence including: MOHAP, DOH, DHA, SEHA, and Dubai Health tender vigilance with historical price and volume reconstruction; hospital and pharmacy-chain consumption analogues covering QIV, high-dose, adjuvanted, and cell-based formulations; physician panels with paediatricians, family medicine specialists, geriatricians, obstetricians, and pulmonologists across all seven emirates; pharmacist-administered vaccination workflow and brand-preference research across the top five community pharmacy chains; payer and TPA interviews spanning Daman, Thiqa, Sukoon, ADNIC, Neuron, and Nextcare; corporate wellness scheme decision-maker interviews at UAE-headquartered employers; and season-over-season KAP (knowledge, attitudes, practices) tracking to quantify hesitancy, formulation preference, and switching drivers. Programmes are governed under EphMRA and BHBIA codes with Arabic–English bilingual instruments.

BioNixus delivers longitudinal hospital consumption analogue analytics, payer and formulary committee qualitative boards, bilingual HCP trackers where relevant, tender and access intelligence aligned to MOHAP licensing, DHA and DOH prior-authorization stacks, and private hospital tier dynamics in the UAE, KOL mapping, and adoption modelling for healthcare and life sciences. Teams receive decision-ready outputs cross-validated against EphMRA and BHBIA governance with GDPR-aligned multinational fieldwork coordinated from London and regional hubs.